logo
A deadly E. coli outbreak in Walkerton, Ont., changed everything 25 years ago

A deadly E. coli outbreak in Walkerton, Ont., changed everything 25 years ago

Bruce Davidson remembers the E. coli outbreak that ravaged his hometown 25 years ago as a 'strange dream.'
The hospital in the small Ontario community of Walkerton usually wasn't busy but it suddenly got inundated with patients experiencing severe diarrhea, vomiting and abdominal pain. The first cases were reported on May 17, 2000.
Soon, the township roughly 140 kilometres north of London, Ont., ran out of diarrhea medication, the emergency department overflowed and air ambulances came to take sick people to other hospitals.
What turned out to be Canada's worst outbreak of E. coli O157 infections, caused by manure-tainted drinking water, ultimately killed seven people and sickened around 2,300.
It was a 'strange dream where you're still you but nothing else is the same,' said Davidson. His own family fell ill and he later formed a citizens' advocacy group in response to the tragedy.
Schools and restaurants were closed, he said, and streets that normally buzzed with children playing on warm spring days felt like a 'ghost town.'
'For the first bit, we were all in shock, but very, very quickly that started to change to anger,' Davidson said in a recent phone interview.
He had heard about waterborne diseases in impoverished parts of the world, but said he never imagined experiencing that in Canada.
The country had the technology, money and infrastructure needed for a safe water supply, 'and yet here we are killing people with drinking water,' he said.
The health crisis caused by a mix of human negligence, lack of resources and natural factors caused countrywide outrage and triggered a public inquiry led by Ontario Justice Dennis O'Connor that lasted for nearly two years.
It was determined that heavy rainfall between May 8 and May 12, 2000 had washed cattle manure from a nearby farm into a well. From there, deadly E. coli bacteria found its way to the municipal water system.
The two brothers who managed the system — Stan and Frank Koebel — pleaded guilty to criminal charges in the case.
The inquiry found that neither brother had the formal training to operate a public utility and water system, that they failed to properly chlorinate the water and that water safety records were falsified.
The inquiry also found that Stan Koebel knew on May 17 that water was contaminated with E. coli but he did not disclose those test results for days. By the time a boil-water advisory was issued on May 21, it was too late.
'It was extremely tragic and even more tragic by the fact that the operators who didn't have proper training and didn't understand that groundwater could make people sick were suppressing the results of tests,' said Theresa McClenaghan, the executive director of the Canadian Environmental Law Association.
McClenaghan, who represented Walkerton's residents during the inquiry, said had the brothers been transparent and told the public about the issue as soon as they knew, many would not become ill.
'But that went on for days and days that people were still drinking this highly contaminated water,' she said.
McClenaghan said the inquiry didn't leave any stone unturned and in the end put out a series of recommendations that now serve as the foundation of water safety regulations, including the province's Safe Drinking Water Act and the Clean Water Act.
The tragedy led to fundamental legislative reforms aimed at strengthening drinking water safety norms, including water source protection, treatment standards, testing and reporting procedures.
Despite the huge progress, access to safe drinking water is still a serious issue, especially in northern Ontario's First Nations communities.
A report released by the Ontario's auditor general in March raised concerns about oversight of non-municipal water systems that include inadequate testing and monitoring and lack of compliance enforcement. Nearly three million Ontarians get their water from a non-municipal system.
While 98 per cent of samples tested from these systems in the past decade have met the provincial drinking water standards, there are weaknesses that need to be addressed to ensure water safety, the report said.
It said about 1.3 million people drink water from private wells, and 35 per cent of the samples taken from them between 2003 and 2022 tested positive for indicators of bacterial contamination.
The report listed recommendations that include increasing testing and oversight, and raising awareness about the risks and availability of testing resources.
'As demonstrated by the Walkerton crisis, the consequences of Ontarians drinking unsafe water can be deadly,' auditor general Shelley Spence wrote.
The Canadian Environmental Law Association and dozens of other organizations have written to the provincial government calling for a 'timely and transparent' implementation of Spence's recommendations.
The mayor of Brockton, Ont., the municipality that includes Walkerton, said he is glad that important reforms have been made since the deadly drinking water contamination.
'The testing that occurs of the municipal drinking water in Ontario now is very rigorous,' Chris Peabody said.
He said 35 people currently work at the Walkerton Clean Water Centre where operators from across Canada are trained on how to provide safe and clean drinking water.
But Peabody didn't want to speak further about the tragedy from 25 years ago, saying it was a traumatic experience for so many people.
Bruce Davidson, the Walkerton resident, said even though the E. coli illnesses in his family weren't as serious as many others, they have all been struggling with the consequences.
He said his wife had sporadic but 'excruciating pain' and severe cramping for around three years, and he and his son are still experiencing 'days when you just don't really want to get too far from a washroom.'
The community has largely moved forward, he said. Housing has expanded and so have schools. The water is probably safer than anywhere else in the province, he said.
After the tragedy, a few residents decided to leave Walkerton but most — including Davidson — stayed.
'Most people looked at it and said, this community is our home. It is worth fighting for,' he said.
This report by The Canadian Press was first published May 17, 2025.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Truemeds Secures USD 85 Mn Series C Funding to Expand Affordable Healthcare Access
Truemeds Secures USD 85 Mn Series C Funding to Expand Affordable Healthcare Access

Entrepreneur

time17 hours ago

  • Entrepreneur

Truemeds Secures USD 85 Mn Series C Funding to Expand Affordable Healthcare Access

The Series C round's first close was led by Accel, followed by a second close led by Peak XV Partners, with significant participation from WestBridge Capital and Info Edge Ventures. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Mumbai-based e-pharmacy and telehealth platform Truemeds has raised USD 85 million in its Series C funding round led by Accel and Peak XV Partners. The round was completed in two tranches. WestBridge Capital and Info Edge Ventures also participated. The company plans to deploy the capital to open additional fulfillment centers in high-demand non-metro regions, strengthen its engineering and product teams with experienced professionals, and establish a new office in Bengaluru to access India's technology talent pool. It also aims to triple its national penetration while expanding into diagnostic services within the next few months. Founded in 2019 by Akshat Nayyar and Dr Kunal Wani, Truemeds offers clinically equivalent alternatives to branded medicines, enabling patients to save between 50 and 70 percent on monthly costs. The platform primarily serves chronic care patients, including those managing diabetes, hypertension, and cardiovascular diseases. Operating in all major locations across the country, the company engages with around 600 doctors daily and employs about 3,000 people, including a 250-member head office team. "Our vision is simple—to bring the lowest prices for medicines in India, while ensuring every patient gets the quality they can trust," said Akshat Nayyar, Co-founder and CEO of Truemeds. "With this funding, we're ready to strengthen our foundation, grow our offerings, and reach deeper into India's non-metro regions, where access to affordable healthcare can truly change lives." The company recently launched its iOS application to reach a broader audience and is preparing to roll out diagnostic services in four pilot cities over the next two quarters. It also plans to integrate artificial intelligence and machine learning tools for product curation, personalized patient journeys, and demand forecasting to enhance supply chain efficiency for pharmaceutical partners. Abhinav Chaturvedi, Partner at Accel, said, "India's healthcare market is undergoing rapid transformation, yet affordability continues to be a major barrier—especially in chronic care. Truemeds is bridging this gap with a clinically guided, technology-led platform that delivers transparency and accessibility at scale." Sakshi Chopra, Managing Director at Peak XV Partners, added, "Their mission to make chronic care affordable for millions, especially in underserved non-metro markets, is both timely and transformative. By leveraging technology to deliver a seamless customer experience, they are redefining how essential medicines reach those who need them the most." With this funding round, Truemeds is positioned to expand its role in India's growing healthcare market, focusing on affordability, accessibility, and innovation in chronic care delivery.

Why investors just bet $85M on this Indian company's generic drug strategy
Why investors just bet $85M on this Indian company's generic drug strategy

Yahoo

timea day ago

  • Yahoo

Why investors just bet $85M on this Indian company's generic drug strategy

With over 400 million chronic patients, India is one of the world's largest medicine markets. But while most e-pharmacies chase speed, affordability remains the real challenge. Truemeds took a different route: helping patients switch to lower-cost substitutes, a bet now paying off with new funding at about four times its previous valuation. The six-year-old startup has raised $85 million in a new round that includes $65 million in primary and $20 million in secondary funding led by Accel, along with participation from Peak XV Partners. TechCrunch first reported on Accel's talks to back Truemeds last year. Existing investors WestBridge Capital and InfoEdge Ventures, also participated. The fresh round has boosted Truemeds' valuation to over $400 million, up from the $110 million in its last round two years ago. Founded in 2019, Truemeds entered the market at a time when India's online pharmacy space was already crowded with major players offering steep discounts on branded generics. But some of those companies struggled to sustain early momentum — Prosus Ventures-backed PharmEasy, for instance, saw its valuation drop from a peak of $5.6 billion to under $600 million, while 1mg was acquired by Tata Digital, part of the Tata Group. Instead of competing head-on, Truemeds' founders chose to focus on a relatively niche segment: generic medicines. 'There is no way to educate the user that you can have more affordable options if you can't afford these drugs,' said Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. 'That is where we felt that nobody in the value chain was working towards that, and we can bridge that gap.' The Mumbai-based recommends generic alternatives to consumers for the branded medicines they need. This eventually helps consumers save money, as generic drugs are typically more affordable than their branded versions due to cost efficiencies in their development process. Truemeds says its differentiated approach has paid off, with revenue growing over 66% year-over-year to ₹5 billion ($57 million) in the last financial year. The startup says it retains more than 15% of its revenue after 12 months and now serves an average of 500,000 customers each month, with a total of 3 million customers to date. Moreover, it says it now serves over 20,000 postal codes across the country, with more than 75% of its customers coming from tier-2 cities and beyond. However, educating customers about alternatives to their prescribed medicines — and convincing them to switch from branded drugs to generics — remains a challenge. 'Because you get anchored to your prescribed brand's price, and when you suddenly see a lower price, you want to know why it is low,' Nayyar told TechCrunch. Increasing discounts while competitors cut back While today's e-pharmacies chase speed over savings, the sector's early playbook was different. Online pharmacies in India used to offer discounts of up to 25% to attract customers. However, Nayyar said this dropped to 20% and then 15% — the new average — as most burned cash to acquire new customers and pivoted to faster delivery as their main differentiator. Meanwhile, Truemeds has gone in the opposite direction, increasing its average discounts from 29% to 32% in the last 12 months. For an average user who switches brands on the platform, savings reach 47% on their medicine, says the company. This comes from Truemeds' deep procurement relationships with pharma companies, where the startup uses its technology to give manufacturers better demand visibility, helping them plan production more efficiently for upcoming quarters, he said. The startup also relies on its own logistics in some of the major cities it operates in and uses low-cost logistics partners for the rest. 'We believe that our four-hour delivery model is more than sufficient from a chronic patient's perspective,' said Nayyar. 'You're able to do more planned purchases that way, but we want to do it in the most efficient manner, and pass more and more discounts to the end user rather than [focus on] the fastest delivery for that matter.' Next up: AI-powered customization and doorstep diagnostics As Truemeds needs to convince customers to choose generics over branded medicines, it goes through deeper consultations with them. It already conducts 10-12 million consultations per year. The startup has developed an algorithm over the years that looks at various parameters to precisely suggest alternatives to the branded drugs a customer demands. It considers nuances such as whether the medicine is sugar-coated if it is for a young patient, where it is manufactured, and whether the plant is GMP-certified, among others. The startup also has a chatbot to address some user queries quickly. Much more is on the roadmap. The company plans to develop an AI-based system that customizes conversations based on customers' behavior and previous interactions with generic alternatives. It's also opening a Bengaluru office while dedicating at least 20% of its capital to engineering and product development. Beyond medicines, Truemeds is plotting to enter diagnostics through partnerships with national pathology labs, planning to pilot lab testing services in some tier-2 cities in the next three to four months. 'The primary mission remains the same, which is making healthcare affordable for the end user,' the co-founder said. 'It started with medicines. Now that the model is getting established, we are going to keep scaling that. Simultaneously, we also want to see if we can do something similar on the diagnostics front, where we can be the lowest cost provider of at least the most common tests.' The startup also plans to increase its fulfillment center count by 300% — from 19 currently — over the next 12 months, aiming to deepen its presence in existing markets. Before this round, Truemeds raised $50 million and still has 30–35% of that capital in the bank, Nayyar said. The startup has a workforce of 2,800 people, with 250 based in its Mumbai office. Sign in to access your portfolio

Why investors just bet $85M on this Indian company's generic drug strategy
Why investors just bet $85M on this Indian company's generic drug strategy

TechCrunch

timea day ago

  • TechCrunch

Why investors just bet $85M on this Indian company's generic drug strategy

With over 400 million chronic patients, India is one of the world's largest medicine markets. But while most e-pharmacies chase speed, affordability remains the real challenge. Truemeds took a different route: helping patients switch to lower-cost substitutes, a bet now paying off with new funding at about four times its previous valuation. The six-year-old startup has raised $85 million in a new round that includes $65 million in primary and $20 million in secondary funding led by Accel, along with participation from Peak XV Partners. TechCrunch first reported on Accel's talks to back Truemeds last year. Existing investors WestBridge Capital and InfoEdge Ventures, also participated. The fresh round has boosted Truemeds' valuation to over $400 million, up from the $110 million in its last round two years ago. Founded in 2019, Truemeds entered the market at a time when India's online pharmacy space was already crowded with major players offering steep discounts on branded generics. But some of those companies struggled to sustain early momentum — Prosus Ventures-backed PharmEasy, for instance, saw its valuation drop from a peak of $5.6 billion to under $600 million, while 1mg was acquired by Tata Digital, part of the Tata Group. Instead of competing head-on, Truemeds' founders chose to focus on a relatively niche segment: generic medicines. 'There is no way to educate the user that you can have more affordable options if you can't afford these drugs,' said Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. 'That is where we felt that nobody in the value chain was working towards that, and we can bridge that gap.' The Mumbai-based recommends generic alternatives to consumers for the branded medicines they need. This eventually helps consumers save money, as generic drugs are typically more affordable than their branded versions due to cost efficiencies in their development process. Truemeds says its differentiated approach has paid off, with revenue growing over 66% year-over-year to ₹5 billion ($57 million) in the last financial year. The startup says it retains more than 15% of its revenue after 12 months and now serves an average of 500,000 customers each month, with a total of 3 million customers to date. Moreover, it says it now serves over 20,000 postal codes across the country, with more than 75% of its customers coming from tier-2 cities and beyond. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW However, educating customers about alternatives to their prescribed medicines — and convincing them to switch from branded drugs to generics — remains a challenge. 'Because you get anchored to your prescribed brand's price, and when you suddenly see a lower price, you want to know why it is low,' Nayyar told TechCrunch. Increasing discounts while competitors cut back While today's e-pharmacies chase speed over savings, the sector's early playbook was different. Online pharmacies in India used to offer discounts of up to 25% to attract customers. However, Nayyar said this dropped to 20% and then 15% — the new average — as most burned cash to acquire new customers and pivoted to faster delivery as their main differentiator. Meanwhile, Truemeds has gone in the opposite direction, increasing its average discounts from 29% to 32% in the last 12 months. For an average user who switches brands on the platform, savings reach 47% on their medicine, says the company. This comes from Truemeds' deep procurement relationships with pharma companies, where the startup uses its technology to give manufacturers better demand visibility, helping them plan production more efficiently for upcoming quarters, he said. The startup also relies on its own logistics in some of the major cities it operates in and uses low-cost logistics partners for the rest. 'We believe that our four-hour delivery model is more than sufficient from a chronic patient's perspective,' said Nayyar. 'You're able to do more planned purchases that way, but we want to do it in the most efficient manner, and pass more and more discounts to the end user rather than [focus on] the fastest delivery for that matter.' Next up: AI-powered customization and doorstep diagnostics As Truemeds needs to convince customers to choose generics over branded medicines, it goes through deeper consultations with them. It already conducts 10-12 million consultations per year. The startup has developed an algorithm over the years that looks at various parameters to precisely suggest alternatives to the branded drugs a customer demands. It considers nuances such as whether the medicine is sugar-coated if it is for a young patient, where it is manufactured, and whether the plant is GMP-certified, among others. The startup also has a chatbot to address some user queries quickly. Much more is on the roadmap. The company plans to develop an AI-based system that customizes conversations based on customers' behavior and previous interactions with generic alternatives. It's also opening a Bengaluru office while dedicating at least 20% of its capital to engineering and product development. Beyond medicines, Truemeds is plotting to enter diagnostics through partnerships with national pathology labs, planning to pilot lab testing services in some tier-2 cities in the next three to four months. 'The primary mission remains the same, which is making healthcare affordable for the end user,' the co-founder said. 'It started with medicines. Now that the model is getting established, we are going to keep scaling that. Simultaneously, we also want to see if we can do something similar on the diagnostics front, where we can be the lowest cost provider of at least the most common tests.' The startup also plans to increase its fulfillment center count by 300% — from 19 currently — over the next 12 months, aiming to deepen its presence in existing markets. Before this round, Truemeds raised $50 million and still has 30–35% of that capital in the bank, Nayyar said. The startup has a workforce of 2,800 people, with 250 based in its Mumbai office.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store